AIDS events among individuals initiating HAART: Do some patients experience a greater benefit from HAART than others?

AIDS

Volumn 19, Issue 17, 2005, Pages 1995-2000

  Sabine, C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

AIDS; HAART; Immunological response; Incidence rate ratios; Virological response

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CALCULATION; CELL COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 27944434257     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000189858.59559.d2     Document Type: Article

References (4)

1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
2. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the EuroSIDA Study. Lancet 2000; 356:291-296.
3. The Antiretroviral Therapy Cohort Collaboration. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165:416-423.
4. Wood E, Montaner JSG, Chan K, Tyndall MW, Schechter MT, Bangsberg D, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002; 16:2065-2072.